Hims, Super Bowl

Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.
Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs
The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.
Hims & Hers Set To Run Impactful Super Bowl Ad
Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss offerings in a way that will generate buzz.
Hims & Hers Super Bowl ad stirs up controversy with lawmakers
Hims & Hers Health (HIMS) stock moves a notch higher Monday morning after the company's weight-loss drug ad played during the Super Bowl. The commercial's airing raised concerns from health experts and US lawmakers over the exclusion of potential side effects tied to GLP-1 weight-loss treatments in the advertisement.
Ozempic, Wegovy maker responds to Hims & Hers Super Bowl ad
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
GLP-1 ad battle—Ozempic and Wegovy maker responds to Hims & Hers Super Bowl debut
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Super Bowl ad sparks controversy over cut-rate Wegovy alternative
Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived deal for consumers.
Hims & Hers Stock Bounces After Super Bowl Ad
Shares of Hims & Hers rose 5.2% Monday after the telehealth provider ran an advertisement on Super Bowl Sunday highlighting the company's efforts to fight the obesity epidemic in America. But Heard on
Hims & Hers' Super Bowl ad sparks backlash
The tele-health company Hims & Hers Health is facing scrutiny after critics say its Super Bowl ad promotes weight loss drugs that are not FDA-approved.
Creatives React: Hims & Hers' Super Bowl Ad Goes for the Gut
Hims & Hers didn't hold back in its debut Super Bowl ad. In an effort to market weight-loss drugs that are "affordable," "doctor-trusted," and "formulated in the USA," the telehealth company went straight for the gut of the American healthcare system.
FiercePharma7h
Pfizer wins 2025 Super Bowl with ad's 'likeability,' while Hims & Hers' spot takes engagement crown: analysts
Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...
Hims & Hers Health: Explosive Growth Potential Ahead
Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.
Hims & Hers Super Bowl Spot Draws Drug-Industry Backlash
Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading' patients
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
What is compounded semaglutide and is it safe? The weight loss drugs Hims & Hers is selling, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business
Telehealth company Hims Hers is pushing the boundaries of drug compounding and testing the limits of regulators.
Superbowl Ad Sparks A Healthy Controversy About Medication Safety
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...